FIELD: biotechnology.
SUBSTANCE: described is a group of inventions which includes a monoclonal antibody iC1 and its antigen-binding fragment, which selectively bind the receptor-binding domain (RBD) of the Spike protein of the SARS-CoV-2 virus, having virus-neutralizing activity. In one version of the invention, the monoclonal antibody or its antigen-binding fragment comprises a heavy chain variable region (VH) containing the amino acid sequence SEQ ID NO: 3, and a light chain variable region (VL) containing the amino acid sequence SEQ ID NO: 4.
EFFECT: invention is aimed at development of a new monoclonal antibody binding to RBD of the Spike protein of the SARS-CoV-2 virus, having high affinity and capable of neutralizing SARS-CoV-2 virus.
7 cl, 7 dwg, 4 tbl, 7 ex
| Title | Year | Author | Number |
|---|---|---|---|
| MONOCLONAL ANTIBODY IC2 AND ITS ANTIGEN-BINDING FRAGMENT, SELECTIVELY BINDING RECEPTOR-BINDING DOMAIN OF SPIKE PROTEIN OF SARS-CoV-2 VIRUS, HAVING VIRUS-NEUTRALIZING ACTIVITY | 2023 |
|
RU2817697C1 |
| MONOCLONAL ANTIBODIES AGAINST THE RECEPTOR-BINDING DOMAIN OF SARS-COV-2 SPIKE PROTEIN AND THEIR ANTIGEN-BINDING FRAGMENTS ENCODING THEIR NUCLEIC ACIDS, AS WELL AS METHODS OF THEIR USE | 2021 |
|
RU2800649C2 |
| SINGLE-DOMAIN LLAMA ANTIBODY H5 AND ITS DERIVATIVE H5-Fc SPECIFICALLY BINDING THE RBD DOMAIN OF THE S-PROTEIN OF THE SARS-CoV-2 VIRUS POSSESSING VIRUS-NEUTRALIZING ACTIVITY | 2022 |
|
RU2793967C1 |
| MONOCLONAL ANTIBODY TO RDB FRAGMENT IN COMPOSITION OF SARS-COV-2 S PROTEIN | 2020 |
|
RU2744274C1 |
| BISPECIFIC MONOCLONAL ANTIBODY AGAINST SARS-COV-2 | 2022 |
|
RU2791749C1 |
| BROADLY NEUTRALIZING ANTIBODY AGAINST SARS-CoV-2 | 2022 |
|
RU2810476C1 |
| POLYPEPTIDE MODULE FOR BINDING CONSERVATIVE EPITOPE OF RECEPTOR-BINDING DOMAIN OF SPIKE PROTEIN OF SARS-CoV-2 CORONAVIRUS | 2022 |
|
RU2809183C1 |
| RECOMBINANT SARS-CoV-2 S PROTEIN RBD-BINDING PROTEIN | 2022 |
|
RU2778942C1 |
| SINGLE-DOMAIN NANO-ANTIBODIES AGAINST SPIKE PROTEIN OF SARS-CoV-2 VIRUS | 2021 |
|
RU2794141C2 |
| HUMANIZED MONOCLONAL ANTIBODY SPECIFICALLY BINDING TO RBD S OF THE PROTEIN OF THE SARS-COV-2 VIRUS, AGENT AND METHOD FOR THERAPY AND EMERGENCY PREVENTION OF DISEASES CAUSED BY SARS-COV-2 VIRUS | 2021 |
|
RU2765731C1 |
